Company intelligence / Profile preview

Acenxion Biosystems

Kansas City, Kansas, United Statesacenxionbiosystems.com ↗

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Acenxion Biosystems has developed an automated system that reduces the time required for phenotypic AST from days to approximately 4 hours. This enables faster targeted antibiotic treatment, improves patient outcomes, reduces healthcare costs, and helps combat antibiotic resistance. The technology fits into existing clinical workflows and has been validated through partnerships with public health labs and hospitals.

Therapeutic areas: Infectious Diseases
Modalities: Automated phenotypic antimicrobial susceptibility testing (AST) systemsrapid bacteria detection in blood cultures
Industry: Molecular Diagnostics

Partnerships

National Institutes of Health (NIH)National Institute of Allergy and Infectious Diseasespublic health laboratorieshospitalsclinics

Beyond the preview

Go deeper on Acenxion Biosystems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acenxion Biosystems.

Explore the full profile